Monday, December 04, 2017
Innovus Pharmaceuticals, Inc., an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the signing of an exclusive license and distribution agreement with Corporacion Pharma Solutions Peru SAC, a Peruvian company (“Pharma Solutions”) for the commercialization of Zestra®, Zestra Glide®, EjectDelay® and Sensum+® in Peru. As part of the agreement, Innovus Pharma will receive an upfront payment and minimum yearly quantity of orders.
The Company expects to ship its first commercial order to Peru within thirty (30) days of Pharma Solutions receiving regulatory approval from the Peru Health Authorities, which is currently expected to be Q1 2018.
“We are pleased to expand our global reach and commercialization market for four of our important men’s and women’s health products, which include Zestra®, Zestra Glide®, EjectDelay® and Sensum+® in Peru,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Pharma Solutions is our 17th distribution partner for our products outside the United States and is our first distributor in South America, a region that we are looking forward to expanding into,” continued Dr. Damaj.
To date, Innovus Pharma has focused on expanding its worldwide footprint: